Zilico appoints new commercial director

Andrew Saipe joins company behind cervical cancer diagnostic system, ZedScan

Andrew Saipe

Zilico has strengthened its team with the appointment of a new commercial director.

Andrew Saipe, who has 25 years experience in medical sales, joins Zilico from Purple Surgical, where he looked after many of the international markets for eight years.

Prior to this, he was a sales manager with Medtronic (Covdien) for five years.

Saipe’s new position at Zilico will see him manage and develop commercial relationships with the company’s distributor network, while also assessing new potential markets for Zilico’s flagship product, ZedScan.

ZedScan is a cervical cancer diagnostic system which utilises patented Electrical Impedance Spectroscopy (EIS) technology to improve the ability to detect cervical intraepithelial neoplasia (CIN) following an abnormal smear result, increasing diagnostic accuracy and delivering health economic benefits.

Saipe said: “With the growing real-clinic evidence of the benefits of ZedScan in the cervical cancer care pathway, this is a very-exciting time to be joining the company.

“I’m now looking forward to using my knowledge of global healthcare to drive commercial growth for ZedScan in both established and emerging international markets.”

Sameer Kothari, chief executive of Zilico, added: “Andrew has an outstanding track record in international healthcare sales and his experience will undoubtedly play a major role in the continuing growth of the company. We’re delighted to welcome him to the team.”

Companies